NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 235)
Posted On: 06/18/2020 4:11:30 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applies for NIH Grant to Support COVID-19 Therapy Studies, Receives Expanded Health Canada License
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled “In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement.” According to the update, the grant application is for funding to support Lexaria’s second round of planned studies related to COVID-19 treatment possibilities. Additionally, the Company also reported that its subsidiary Lexaria CanPharm ULC has received a new license from Health Canada, issued in accordance with the Cannabis Act and Cannabis Regulations. The new license allows for expanded testing capabilities including sensory testing of cannabis oral products for taste, smell, and additional research and evaluation.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled “In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement.” According to the update, the grant application is for funding to support Lexaria’s second round of planned studies related to COVID-19 treatment possibilities. Additionally, the Company also reported that its subsidiary Lexaria CanPharm ULC has received a new license from Health Canada, issued in accordance with the Cannabis Act and Cannabis Regulations. The new license allows for expanded testing capabilities including sensory testing of cannabis oral products for taste, smell, and additional research and evaluation.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)